Evidence map›Paper›PMID 42337141›Full record

ArticleJournal of patient-reported outcomes2026

Characterizing and quantifying disease impacts of generalized myasthenia gravis (gMG) in the United States: insights from patient and caregiver interviews and surveys.

Pushpa Narayanaswami, Jamie Sullivan, Craig Thiele, Christina Ramirez, Susan dosReis, Allison Foss, Karen S Yee, Mayvis Rebeira, Naila Wahid, Alexis C Garduno and 3 more

Abstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pushpa NarayanaswamiBeth Israel Deaconess Medical Center/Harvard Medical School, Boston, USA. pnarayan@bidmc.harvard.edu.
Jamie SullivanEveryLife Foundation for Rare Diseases, Washington DC, USA.
Craig ThieleHealth Management Associates, Dayton, USA.
Christina RamirezPatient Consultant, Rogers, USA.
Susan dosReisUniversity of Maryland School of Pharmacy, Baltimore, USA.
Allison FossMyasthenia Gravis Association, Kansas City, USA.
Karen S YeeAlexion, AstraZeneca Rare Disease, Boston, USA.
Mayvis RebeiraAlexion, AstraZeneca Rare Disease, Boston, USA.
Naila WahidAvalere Health, Washington DC, USA.
Alexis C GardunoAvalere Health, Washington DC, USA.
Elizabeth CrevierAvalere Health, Washington DC, USA.
Christine RoweAlexion, AstraZeneca Rare Disease, Boston, USA.
Kelly G GwathmeyVirginia Commonwealth University School of Medicine, Richmond, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment value is traditionally assessed through clinical benefits, health-related quality of life, and healthcare utilization. However, rare diseases such as generalized myasthenia gravis (gMG) that heavily affect families and/or caregivers require a more holistic approach that centers around impacted individuals across all areas of daily life. Here, key domains impacted by gMG were identified through individual interviews with both patients and caregivers and these impacts were further assessed through a survey in an independent sample.

methodsInterviews with patients with gMG and caregivers identified 25 patient-centered "impact elements" across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety). Independently recruited patients and caregivers who completed a subsequent electronic, quantitative survey rated the relevance of impact elements on a scale of 1 (lowest) to 5 (highest).

resultsRespondents included 239 patients with gMG (63%, aged 18-49 y; 69%, female) and 81 caregivers (58%, aged 18-49 y; 42% female). The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers. Numerically higher impact scores were observed among patients with more severe disease, younger patients, and caregivers who were unemployed, retired, or disabled.

conclusionsThese findings provide additional insight into the comprehensive burden of gMG that extends beyond symptoms and medical costs.

Indexed as

CaregiversCost of IllnessMyasthenia GravisQuality of LifeAdolescentAdultAgedFemaleHumansInterviews as TopicMaleMiddle AgedSurveys and QuestionnairesUnited StatesYoung AdultCaregiverDisease burdengMGInterviewMyasthenia gravisSurvey

Identifiers

PMID42337141
PMCPMC13400517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.